argenx

ARGX · Nasdaq · Netherlands

Share price · ARGX

$941.25-51.74 (-5.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 310K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ARGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Oct 2026-11.8%
  2. 17 Aug 2026+16.0%
  3. 23 Jul 2026+8.6%
  4. 23 Jun 2026-5.6%

    Nothing announced by ARGX that day or the session before.

  5. 5 Jun 2026+5.8%

    Nothing announced by ARGX that day or the session before.

  6. 14 May 2026+2.4%

    Nothing announced by ARGX that day or the session before.

  7. 11 May 2026+4.0%

    Nothing announced by ARGX that day or the session before.

  8. 26 Feb 2026-5.6%
  9. 27 Jan 2026+3.8%

    Nothing announced by ARGX that day or the session before.

  10. 5 Jan 2026-4.7%

    Nothing announced by ARGX that day or the session before.

Share of unusual movement by asset

For each asset, the share of ARGX's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Efgartigimod Alfa (Vyvgart)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—39%
Sessions with no dated event—61%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
FcRnAntibody fragment
Myasthenia GravisChronic Inflammatory Demyelinating Polyneuropathy
Generalized Myasthenia Gravis
Approved
FcRnAntibody fragment
Chronic Inflammatory Demyelinating PolyneuropathyMyasthenia Gravis
Generalized Myasthenia Gravis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY——$702M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2022-FY——$238M—report ↗
2021-FY——$523M—report ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.